Myriad Genetics, Inc.

MYGN

US62855J1043

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 04:00:00 2025-01-10 pm EST			5-day change	1st Jan Change
14.83 ^USD	+0.34%		+8.49%	+8.17%

Jan. 07	Myriad Genetics Forms 5-Year Alliance With MD Anderson to Evaluate Molecular Residual Disease Assay	MT
Dec. 20	Myriad Genetics, Inc.(NasdaqGS:MYGN) dropped from NASDAQ Biotechnology Index	CI

Myriad Genetics Says Fetal Gender Test Available at Over 8,000 Stores in US

November 13, 2024 at 10:29 am EST

This article is reserved for members

Already a member?

Not a member ?

Free registration

Latest news about Myriad Genetics, Inc.

Myriad Genetics Forms 5-Year Alliance With MD Anderson to Evaluate Molecular Residual Disease Assay	Jan. 07	MT
Myriad Genetics, Inc.(NasdaqGS:MYGN) dropped from NASDAQ Biotechnology Index	Dec. 19	CI
Top Premarket Decliners	Dec. 12	MT
Myriad Genetics Expects to Reach Resolution With UnitedHealthcare Over Pharmacogenetic Testing Before Yearend	Dec. 11	MT
Myriad Genetics Elects Mark S. Davis as New Board Member	Dec. 10	CI
Leerink Partners Downgrades Myriad Genetics to Market Perform From Outperform, Cuts Price Target to $21 From $30	Dec. 09	MT
Myriad Genetics, Inc. Announces Updates to Its Agreement with Illumina Inc	Nov. 20	CI
Sintx Technologies, Inc. Appoints Gregg R. Honigblum as Chief Strategy Officer	Nov. 19	CI
Morgan Stanley Cuts Price Target on Myriad Genetics to $21 From $32, Keeps Equalweight Rating	Nov. 18	MT
Myriad Genetics Says Fetal Gender Test Available at Over 8,000 Stores in US	Nov. 13	MT
Myriad Genetics, Inc. Expands Access to At-Home Early Fetal Sex DNA Test with Retail Launch	Nov. 13	CI
(MYGN) MYRIAD GENETICS Forecasts Fiscal Year 2024 EPS Range $0.12 - $0.14	Nov. 07	MT
Earnings Flash (MYGN) MYRIAD GENETICS Posts Q3 EPS $0.06	Nov. 07	MT
Earnings Flash (MYGN) MYRIAD GENETICS Reports Q3 Revenue $213M	Nov. 07	MT
Myriad Genetics, Inc., Q3 2024 Earnings Call, Nov 07, 2024	Nov. 07
Myriad Genetics, Inc. Reports Impairment Charges for the Third Quarter Ended September 30, 2024	Nov. 07	CI
Myriad Genetics, Inc. Revises Earnings Guidance for the Year 2024	Nov. 07	CI
Myriad Genetics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	Nov. 07	CI
Myriad Genetics in Active Talks with UnitedHealthcare to Keep Coverage of GeneSight	Nov. 04	DJ
Myriad Genetics Disputes Inclusion of GeneSight in UnitedHealthcare's Coverage Restriction	Nov. 04	MT
Myriad Genetics and Flatiron Health Partner to Make Genetic Testing More Accessible with Electronic Medical Record Integration	24-10-15	CI
Myriad Genetics, Inc. - Analyst/Investor Day	24-10-09
Myriad Genetics, Inc. Provides Earnings Guidance for the Third Quarter 2024 and Reaffirms Earnings Guidance for the Full-Year 2024	24-10-09	CI
Myriad Genetics Outlines Five Projects on Studying Breast Cancer Test	24-10-08	MT
Myriad Genetics Announces Five Research Collaborations to Study the Use of MRD Testing in Breast Cancer	24-10-08	CI

Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test which can reveal a baby's gender as early as six weeks into pregnancy. The Companyâs testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor Test, Precise Liquid Test, SneakPeek and GeneSight, among others.

Employees

2,700

Sector

Medical Equipment, Supplies & Distribution

Calendar

2025-01-15 - JP Morgan Healthcare Conference

More about the company